Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CPA3 | P15088 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20179140 | 1.00 | FOLH1 (0.61) | FOLH1ALDH1A1L3MBTL1CPA3CYP1A2 | |
| SCHEMBL15247509 | 0.85 | CYP1A2 (0.63) | FOLH1CPA3CYP1A2CPA1 | |
| SCHEMBL12418042 | 0.85 | CYP1A2 (0.63) | FOLH1CPA3CYP1A2CPA1 | |
| SCHEMBL21577935 | 0.83 | CPA3 (0.44) | FOLH1CPA3CYP1A2CPA1 | |
| SCHEMBL20168567 | 0.82 | FOLH1 (0.68) | FOLH1ANPEPENPEP | |
| SCHEMBL14508892 | 0.82 | FOLH1 (0.68) | FOLH1ANPEPENPEP | |
| SCHEMBL21577999 | 0.82 | FOLH1 (0.68) | FOLH1ANPEPENPEP | |
| SCHEMBL20168304 | 0.82 | SMN1; SMN2 (0.46) | FOLH1CYP1A2 | |
| SCHEMBL20168303 | 0.82 | CYP4F2 (0.49) | FOLH1ALDH1A1CPA3CYP1A2 | |
| SCHEMBL21577936 | 0.81 | ALDH1A1 (0.45) | FOLH1ALDH1A1L3MBTL1ANPEPENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059775-B2 | Prodrug compositions and utility of hydroxamate-based GCPII inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190352255-A1 | NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS | THE JOHNS HOPKINS UNIVERSITY | 2019-11-21 | — | — | US | disclosed |
| WO-2018094334-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352255-A1 | NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS | GPI, TPI1, HPGDS | FOLH1 10/4885ALDH1A1 1963/4885L3MBTL1 2834/4885 |
| US-11059775-B2 | Prodrug compositions and utility of hydroxamate-based GCPII inhibitors | GLS, HPGDS, GPI | FOLH1 15/4885ALDH1A1 1758/4885L3MBTL1 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.